Redox Modification and Targeting of Mutant KRas in Cancer
癌症中突变 KRa 的氧化还原修饰和靶向
基本信息
- 批准号:10595875
- 负责人:
- 金额:$ 19.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-05-01 至 2023-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
ABSTRACT
Oncogenic mutation of KRAS is a signature event in progression and growth of pancreatic cancer, an almost
universally fatal disease. Oncogenic KRAS allele expression leads to metabolic changes and altered cellular signaling
pathways that both stimulate the production of intracellular reactive oxygen species (ROS). Increases in ROS drive
formation and progression of pancreatic precancerous lesions by upregulating survival and growth factor signaling
pathways. Despite ROS dysregulation being central to cancer cell proliferation, as exemplified by KRas-induced
tumorigenesis, the mechanisms underlying ROS-dependent neoplasia remain very poorly understood. Elucidation
and characterization of the redox-dependent ‘switches’ that support ROS-driven neoplasia have been severely
hampered by the lack of direct methods to examine oxidative cysteine modifications in their native cellular
environment. Our laboratory has addressed this challenge through the development of a chemoproteomic approach
for in situ detection of the prototypical protein biomarker of redox signaling and stress, known as cysteine sulfenic acid
(Cys-SOH or S-sulfenylation). Here, we apply state-of-the-art methods to accomplish our major objectives of: 1) site-
specific mapping and characterization of KRasmut-dependent cysteine-based redox ‘switches’ that support
development of pancreatic cancer, and 2) examining the tumorigenic potential and pharmacological impact of
oxidative modification at the acquired cysteine in mutant KRasG12C. Successful completion of this project will identify
oxidative cysteine modification as an integral feature of processes that initiate pancreatic cancer through mutant KRas.
It will also delineate the relationship between oxidative modification of the redox-active thiol of KRasG12C to its
tumorigenic potency and the efficacy of small-molecules designed to target this mutant. It will also define the role of
redox in tumorigenic potency of KRasG12C and the efficacy of small-molecules designed to target this mutant. In
addition to KRas itself, the molecular components of redox pathways identifying during this study may represent
new biomarkers and drug targets for the early diagnosis and treatment of pancreatic cancer.
抽象的
KRAS 的致癌突变是胰腺癌进展和生长的标志性事件,几乎是一种
普遍致命的疾病。致癌 KRAS 等位基因表达导致代谢变化和细胞信号传导改变
刺激细胞内活性氧(ROS)产生的途径。 ROS 驱动力增加
通过上调生存和生长因子信号传导来促进胰腺癌前病变的形成和进展
途径。尽管 ROS 失调是癌细胞增殖的核心,如 KRas 诱导的那样
尽管对于肿瘤发生来说,ROS 依赖性肿瘤形成的机制仍然知之甚少。说明
支持 ROS 驱动肿瘤形成的氧化还原依赖性“开关”的表征已受到严重影响
由于缺乏直接方法来检查其天然细胞中的氧化半胱氨酸修饰而受到阻碍
环境。我们的实验室通过开发化学蛋白质组学方法解决了这一挑战
用于原位检测氧化还原信号和应激的原型蛋白质生物标志物,称为半胱氨酸磺酸
(Cys-SOH 或 S-磺酰化)。在这里,我们应用最先进的方法来实现我们的主要目标:1) 站点-
KRasmut 依赖的基于半胱氨酸的氧化还原“开关”的特定映射和表征,支持
胰腺癌的发展,以及 2) 检查其致瘤潜力和药理学影响
突变体 KRasG12C 中获得性半胱氨酸的氧化修饰。该项目的成功完成将确定
氧化半胱氨酸修饰是通过突变 KRas 引发胰腺癌的过程的一个组成部分。
它还将描述 KRasG12C 的氧化还原活性硫醇的氧化修饰与其
致瘤效力和针对该突变体设计的小分子的功效。它还将定义以下角色:
氧化还原对 KRasG12C 致瘤能力的影响以及针对该突变体设计的小分子的功效。在
除了 KRas 本身之外,本研究期间确定的氧化还原途径的分子成分可能代表
用于胰腺癌早期诊断和治疗的新生物标志物和药物靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kate Suzanne Carroll其他文献
Kate Suzanne Carroll的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kate Suzanne Carroll', 18)}}的其他基金
Redox Modification and Targeting of Mutant KRas in Cancer
癌症中突变 KRa 的氧化还原修饰和靶向
- 批准号:
10162539 - 财政年份:2018
- 资助金额:
$ 19.38万 - 项目类别:
Redox Modification and Targeting of Mutant KRas in Cancer
癌症中突变 KRa 的氧化还原修饰和靶向
- 批准号:
9912729 - 财政年份:2018
- 资助金额:
$ 19.38万 - 项目类别:
Nucleophilic Inhibitors for Targeting Redox-Sensitive Kinases
用于靶向氧化还原敏感激酶的亲核抑制剂
- 批准号:
9187426 - 财政年份:2013
- 资助金额:
$ 19.38万 - 项目类别:
Nucleophilic Inhibitors for Targeting Redox-Sensitive Kinases
用于靶向氧化还原敏感激酶的亲核抑制剂
- 批准号:
8969670 - 财政年份:2013
- 资助金额:
$ 19.38万 - 项目类别:
Nucleophilic Inhibitors for Targeting Redox-Sensitive Kinases
用于靶向氧化还原敏感激酶的亲核抑制剂
- 批准号:
8776280 - 财政年份:2013
- 资助金额:
$ 19.38万 - 项目类别:
Nucleophilic Inhibitors for Targeting Redox-Sensitive Kinases
用于靶向氧化还原敏感激酶的亲核抑制剂
- 批准号:
8631369 - 财政年份:2013
- 资助金额:
$ 19.38万 - 项目类别:
Probing the role of cysteine sulfenylation in cell signaling
探讨半胱氨酸磺酰化在细胞信号传导中的作用
- 批准号:
8653970 - 财政年份:2012
- 资助金额:
$ 19.38万 - 项目类别:
Probing the role of cysteine sulfenylation in cell signaling
探讨半胱氨酸磺酰化在细胞信号传导中的作用
- 批准号:
8342423 - 财政年份:2012
- 资助金额:
$ 19.38万 - 项目类别:
Chemical Tools for Probing Cysteine Sulfenation and Sulfination Redox Biology
用于探测半胱氨酸磺化和磺化氧化还原生物学的化学工具
- 批准号:
10658440 - 财政年份:2012
- 资助金额:
$ 19.38万 - 项目类别:
Probing the role of cysteine sulfenylation in cell signaling
探讨半胱氨酸磺酰化在细胞信号传导中的作用
- 批准号:
9380891 - 财政年份:2012
- 资助金额:
$ 19.38万 - 项目类别:
相似海外基金
SunFit Project: skin cancer prevention through behavioral risk factor modification targeting sun and ultraviolet exposure practices using sex/gender and community-specific approaches
SunFit 项目:通过针对阳光和紫外线暴露实践的行为风险因素修正,使用性别和社区特定方法来预防皮肤癌
- 批准号:
460542 - 财政年份:2021
- 资助金额:
$ 19.38万 - 项目类别:
Operating Grants
SunFit Project: Skin cancer prevention through behavioural risk factor modification targeting sun and ultraviolet exposure practices using gender- and community-specific approaches
SunFit 项目:通过针对阳光和紫外线暴露实践的行为风险因素修正,使用针对性别和社区的方法来预防皮肤癌
- 批准号:
458794 - 财政年份:2021
- 资助金额:
$ 19.38万 - 项目类别:
Studentship Programs
Development of novel therapy of osteosarcoma targeting the post-transcriptional modification
针对转录后修饰的骨肉瘤新疗法的开发
- 批准号:
20K16325 - 财政年份:2020
- 资助金额:
$ 19.38万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of novel therapy for leukemia targeting metabolism-dependent protein modification
开发针对代谢依赖性蛋白质修饰的白血病新疗法
- 批准号:
19K17833 - 财政年份:2019
- 资助金额:
$ 19.38万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel antibody therapy targeting tumor specific sugar-chain modification in tumor cells and cancer associated fibroblasts
针对肿瘤细胞和癌症相关成纤维细胞中肿瘤特异性糖链修饰的新型抗体疗法
- 批准号:
19K22361 - 财政年份:2019
- 资助金额:
$ 19.38万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Redox Modification and Targeting of Mutant KRas in Cancer
癌症中突变 KRa 的氧化还原修饰和靶向
- 批准号:
10162539 - 财政年份:2018
- 资助金额:
$ 19.38万 - 项目类别:
Development of anti-cancer strategy by targeting tRNA modification enzymes
以tRNA修饰酶为靶点开发抗癌策略
- 批准号:
18K15241 - 财政年份:2018
- 资助金额:
$ 19.38万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Novel drug discovery and application of intractable cancer targeting RNA m6A modification
靶向RNA m6A修饰的难治性癌症新药发现及应用
- 批准号:
18K16356 - 财政年份:2018
- 资助金额:
$ 19.38万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Redox Modification and Targeting of Mutant KRas in Cancer
癌症中突变 KRa 的氧化还原修饰和靶向
- 批准号:
9912729 - 财政年份:2018
- 资助金额:
$ 19.38万 - 项目类别:
Attempts of plant mitochondrial genome modification via mitochondria-targeting TALENs
通过线粒体靶向 TALEN 修饰植物线粒体基因组的尝试
- 批准号:
17K19256 - 财政年份:2017
- 资助金额:
$ 19.38万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)